Last updated: October 5, 2026
Versed is the original brand associated with midazolam, a short-acting benzodiazepine used for procedural sedation, anesthesia induction, intensive-care sedation, and seizure management. Its commercial trajectory is mature and largely genericized. Roche’s original branded product no longer has the economic profile of a protected innovator medicine; current value is concentrated in generic injectable supply, hospital contracts, dosage-form availability, and shortage resilience.
Standalone revenue for Versed is not publicly disclosed. Public company filings generally report midazolam within broader hospital injectable, anesthesia, or generic portfolios rather than as a separate product. The commercial opportunity is therefore best assessed through market structure, volume demand, generic competition, supply conditions, and the absence of meaningful remaining U.S. exclusivity.
What is Versed and how is midazolam used?
Versed is the brand name for midazolam, a short-acting central nervous system depressant in the benzodiazepine class. It produces sedation, anxiolysis, anterograde amnesia, and anticonvulsant activity.
| Attribute |
Versed / midazolam |
| Active ingredient |
Midazolam hydrochloride |
| Drug class |
Benzodiazepine |
| Primary uses |
Procedural sedation, anesthesia induction, ICU sedation, seizure control |
| Common dosage forms |
Injectable solution, oral syrup; other midazolam products include nasal and buccal formulations |
| U.S. regulatory status |
Legacy FDA-approved product with extensive generic competition |
| Controlled-substance status |
Schedule IV in the United States |
| Original commercial position |
Branded innovator product |
| Current commercial position |
Mature, largely genericized hospital medicine |
The injectable product remains the core hospital application. It is used in endoscopy, emergency medicine, interventional radiology, dentistry, surgery, and critical care. Midazolam is also used in combination with opioids, particularly fentanyl, although the combination increases respiratory-depression risk.
The product’s pharmacology supports rapid onset and relatively short duration, but its use can be displaced by propofol, dexmedetomidine, lorazepam, ketamine, and nonbenzodiazepine sedation protocols depending on the clinical setting.
What is the financial trajectory for Versed?
Versed’s branded revenue trajectory is mature-to-declining, while total midazolam demand is comparatively stable.
The financial pattern has four phases:
- Branded growth: Versed gained adoption as a short-acting injectable benzodiazepine for procedural and perioperative sedation.
- Patent and generic erosion: Generic midazolam entered after the original exclusivity period, reducing branded pricing power.
- Portfolio commoditization: Hospital buyers shifted procurement toward approved generics and contract suppliers.
- Stable volume with low unit economics: Demand remains recurring, but revenue depends on volume, supply continuity, and contract access rather than innovation-based pricing.
Roche does not report current standalone Versed sales in its public financial disclosures. Generic manufacturers also typically aggregate midazolam revenue with broader injectable portfolios. As a result, no reliable public figure exists for annual global Versed sales or a single manufacturer’s midazolam revenue.
What drives midazolam revenue today?
The principal revenue drivers are:
- Procedure volumes in hospitals and ambulatory surgery centers
- Endoscopy and interventional procedure demand
- ICU admissions and sedation protocols
- Emergency-department use
- Generic contract awards
- Availability of injectable presentations
- Manufacturing reliability and shortage conditions
- Volume-based price competition
Price increases can occur during supply disruptions, but these increases are generally episodic. The long-term economic model remains low-margin generic supply rather than branded pharmaceutical pricing.
How large is the competitive market for midazolam?
The market is fragmented across generic injectable suppliers, specialty pharmaceutical companies, and hospital-distributed products. U.S. competition has included manufacturers such as Pfizer, Hikma, Fresenius Kabi, Sagent Pharmaceuticals, and other suppliers depending on presentation and period.
| Competitive category |
Representative products or alternatives |
Commercial effect |
| Generic midazolam injection |
Multiple approved suppliers |
Direct price and contract competition |
| Oral midazolam |
Generic oral syrup products |
Limited institutional and pediatric use |
| Intranasal midazolam |
Nayzilam and other products |
Expands seizure-treatment competition outside Versed |
| Propofol |
Generic injectable |
Major procedural and anesthesia substitute |
| Dexmedetomidine |
Precedex and generics |
ICU and procedural sedation substitute |
| Lorazepam |
Generic injectable and oral products |
Alternative benzodiazepine |
| Ketamine |
Generic injectable |
Alternative for selected sedation settings |
| Fentanyl combinations |
Generic opioid products |
Often used alongside, rather than instead of, midazolam |
Midazolam benefits from established clinician familiarity, broad hospital use, and low acquisition cost. Its disadvantages include respiratory depression, hypotension, prolonged sedation in some patients, and growing preference for alternative sedation protocols in selected intensive-care settings.
When did Versed lose exclusivity?
Versed lost meaningful U.S. market exclusivity many years ago. The core injectable product is a legacy medicine, and generic midazolam products have been available for decades.
The original Versed regulatory approvals date to the 1980s and 1990s, depending on the dosage form. FDA records identify midazolam injection as an established approved product, while the Orange Book lists approved generic equivalents and therapeutic equivalents where applicable (FDA, n.d.-a; FDA, n.d.-b).
| Exclusivity factor |
Current assessment |
| Original compound exclusivity |
Expired |
| Original product patent protection |
Expired or commercially irrelevant |
| Data exclusivity |
Expired |
| Current branded pricing protection |
None of material significance |
| Generic substitution |
Established |
| Biosimilar exposure |
Not applicable |
| Current commercial barrier |
Manufacturing, supply, contracting, and regulatory compliance |
Versed does not have biosimilar risk because midazolam is a small-molecule drug, not a biologic. The relevant competitive threat is generic substitution and therapeutic substitution.
What patents protect Versed and midazolam?
No active composition-of-matter patent is expected to protect the original Versed product in the United States. Midazolam is an established small molecule, and the key commercial patents associated with the original product expired long ago.
The current patent landscape is more relevant to newer delivery systems than to Versed itself. Patent protection may arise around:
- Intranasal delivery devices
- Buccal or transmucosal formulations
- Concentration and excipient systems
- Unit-dose packaging
- Combination products
- Specialized seizure-rescue delivery methods
Those patents generally protect differentiated midazolam products, not the legacy Versed injection. For example, intranasal midazolam products used for seizure clusters may have separate formulation, device, and method-of-use rights from the original injectable product.
A current Orange Book review is the relevant source for identifying listed patents and regulatory exclusivities for a specific NDA. The absence of meaningful current patent protection explains why generic midazolam suppliers compete primarily on price, availability, quality records, and procurement relationships.
What is the Orange Book status of Versed?
The Orange Book status is consistent with a mature reference product and established generic competition.
The commercially relevant points are:
- Versed is an older reference-listed drug.
- Generic midazolam products have been approved under abbreviated new drug applications.
- Generic competition is available for injectable presentations.
- Current commercial protection does not depend on an active branded patent estate.
- Any remaining patent issues would need to be assessed by NDA, dosage form, and listed product presentation.
Orange Book analysis must distinguish among injectable products, oral syrup, and newer nasal formulations. A patent position associated with one midazolam product should not be assumed to apply to all midazolam dosage forms.
Are there Paragraph IV challenges to Versed?
Paragraph IV litigation is not a major current risk factor for legacy Versed. Generic midazolam entered the market after the principal patent and exclusivity barriers had expired or become commercially immaterial.
Paragraph IV litigation typically matters when a generic applicant challenges an unexpired patent listed for a branded reference product. For Versed, the more important competitive event was historical generic entry rather than current patent litigation.
No material, ongoing branded-versus-generic Paragraph IV dispute is central to the current Versed market based on the mature status of the product. Litigation risk may arise in newer midazolam delivery systems, but that risk belongs to the specific product owner and formulation patent estate, not automatically to Versed injection.
What patent litigation affects midazolam products?
The main legal risks are product-specific:
Generic injectable midazolam
Litigation risk is low relative to newer branded medicines. Potential disputes would more likely involve:
- Manufacturing processes
- Labeling and failure-to-warn claims
- Product contamination or sterility
- Shortage-related contract disputes
- Controlled-substance compliance
- Procurement and antitrust issues
Intranasal midazolam
Newer nasal products may have more meaningful formulation, device, and method-of-use rights. These products can face:
- Paragraph IV challenges
- Patent infringement disputes
- Orange Book listing disputes
- Device-related design-around strategies
- Settlement agreements governing generic entry
Safety and product liability
Midazolam products carry litigation exposure related to respiratory depression, dosing errors, medication administration, and use with opioids. These cases generally affect liability expense and risk management rather than patent exclusivity.
What are the FDA regulatory and supply dynamics?
FDA regulation is a major operational factor because injectable midazolam requires sterile manufacturing, validated aseptic processes, controlled-substance handling, and reliable quality systems.
Generic injectable suppliers face higher manufacturing barriers than suppliers of simple oral solid products. The barriers include:
- Sterile fill-finish capacity
- Inspection readiness
- Batch-release controls
- Container-closure integrity
- Controlled-substance recordkeeping
- Sourcing of active pharmaceutical ingredient
- Redundant manufacturing capacity
These barriers can support pricing during shortages even when no patent protects the product. They do not create durable branded exclusivity because other approved manufacturers can enter or expand capacity when economically viable.
The FDA has periodically reported shortages involving injectable medicines, particularly products affected by manufacturing interruptions, raw-material constraints, facility shutdowns, or demand surges. Midazolam’s hospital importance means that supply disruptions can produce temporary increases in purchasing urgency and supplier leverage (FDA, n.d.-c).
What generic entry risks exist for Versed?
Generic entry is no longer an emerging risk; it is the defining structure of the market. The principal risk to any remaining branded Versed revenue is continued substitution by approved generic suppliers.
| Risk |
Impact on Versed |
| Generic price competition |
High |
| Hospital formulary substitution |
High |
| Contract-manufacturer switching |
High |
| Therapeutic substitution |
Moderate |
| Shortage-driven price volatility |
Moderate to high |
| New branded delivery systems |
Moderate |
| Biosimilar competition |
None |
| Patent expiration risk |
Low because core protection is already expired |
A generic launch scenario for a new supplier would most likely involve incremental share capture through a group purchasing organization, hospital system contract, or shortage-related allocation. It would not normally create a major change in total midazolam demand.
How strong is the Versed patent estate?
The patent estate is weak from a current commercial perspective because the original product is old, genericized, and not protected by a meaningful composition-of-matter patent.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Core injectable formulation protection |
Expired or immaterial |
| Method-of-use protection |
Limited commercial relevance |
| Device protection |
Relevant mainly to newer nasal products |
| Manufacturing know-how |
Moderate operational value |
| Freedom to operate for generic injection |
Broad, subject to product-specific review |
| Litigation leverage |
Low for legacy Versed |
Manufacturing know-how can still matter. A supplier with dependable sterile production, low defect rates, and strong regulatory performance can retain share despite limited patent protection. That advantage is operational rather than legal.
Are there licensing deals involving Versed or midazolam?
No major current licensing transaction is publicly associated with legacy Versed as a standalone commercial asset. The original product was historically associated with Roche, while later commercial supply has involved multiple generic manufacturers.
Licensing activity is more relevant to newer midazolam products, including:
- Intranasal seizure-rescue products
- Pediatric formulations
- Buccal or transmucosal delivery systems
- Regional distribution rights
- Device-enabled drug products
These agreements may transfer rights to a formulation, device, or indication rather than to the underlying midazolam molecule. A license involving a newer midazolam product should not be treated as evidence of renewed exclusivity for Versed injection.
How does Versed compare with competing sedation drugs?
| Drug |
Main advantage |
Main commercial pressure against midazolam |
| Midazolam |
Familiarity, rapid onset, low generic cost |
Respiratory depression and variable recovery |
| Propofol |
Rapid recovery and strong procedural profile |
Requires close monitoring; hypotension risk |
| Dexmedetomidine |
Sedation with less respiratory depression in selected settings |
Higher cost and hemodynamic effects |
| Lorazepam |
Familiar benzodiazepine alternative |
Longer duration and less favorable recovery in some uses |
| Ketamine |
Analgesia and dissociative sedation |
Different adverse-effect profile and use case |
| Fentanyl |
Potent analgesia |
Often combined with midazolam rather than replacing it |
Midazolam remains commercially resilient where low acquisition cost and clinician familiarity outweigh recovery-time or respiratory-safety considerations. Propofol and dexmedetomidine exert the greatest pressure in procedural and ICU settings, while other products compete by indication.
What is the geographic coverage of Versed?
Midazolam is marketed globally under multiple brand names and through generic suppliers. The regulatory and commercial position differs by jurisdiction:
- The United States has extensive generic competition and hospital-contract purchasing.
- Europe has broad generic availability, with country-specific reimbursement and procurement systems.
- Emerging markets may rely more heavily on local manufacturers and tender pricing.
- Controlled-substance rules, import requirements, and sterile manufacturing standards affect supply by country.
- Newer nasal or buccal products may have stronger protection in selected jurisdictions than injectable midazolam.
The molecule has broad geographic use, but geographic sales are not equivalent to Versed-branded sales. Most current volume is likely supplied under generic or local brand names.
What is the revenue exposure for manufacturers?
For large pharmaceutical companies, midazolam is usually a small component of a diversified hospital-products portfolio. Revenue exposure is greatest for smaller generic manufacturers with concentrated injectable portfolios.
The financial sensitivity is driven by:
- Contract renewal rates
- Number of approved competitors
- Manufacturing utilization
- API costs
- Sterile facility compliance
- Shortage allocations
- Product recalls
- Hospital purchasing concentration
A supplier with limited competitors can experience temporary revenue expansion during shortages. Once additional capacity returns, price and share often normalize. This makes midazolam a volume-and-supply business, not a durable high-margin franchise.
Key Takeaways
- Versed is the legacy brand for midazolam, a mature short-acting benzodiazepine.
- The original product has no meaningful remaining U.S. patent or exclusivity advantage.
- Generic injectable midazolam is the primary commercial market.
- Standalone Versed revenue is not publicly disclosed by Roche or generic manufacturers.
- Total midazolam demand is stable, supported by procedural sedation, anesthesia, emergency medicine, and ICU use.
- Revenue is constrained by low generic pricing and hospital procurement competition.
- Sterile manufacturing, quality compliance, controlled-substance handling, and supply reliability are the main barriers to entry.
- Propofol and dexmedetomidine are important therapeutic competitors.
- Biosimilar risk is not applicable because midazolam is a small molecule.
- Newer intranasal and transmucosal midazolam products may have stronger formulation, device, and method-of-use protection than legacy Versed injection.
- The principal financial upside is shortage-driven or contract-driven share gain, not patent-protected price expansion.
FAQs About Versed and Midazolam
Is Versed still sold as a branded drug?
The Versed name is associated with the original branded midazolam product, but current U.S. hospital use is primarily supplied through generic midazolam products and institutional purchasing channels.
Is midazolam a blockbuster drug?
No. Midazolam is a high-volume legacy hospital medicine, but generic pricing and fragmented supplier competition prevent blockbuster-style revenue economics.
Can a generic manufacturer launch midazolam without a Paragraph IV challenge?
Yes. For a product without relevant unexpired listed patents, a generic applicant can pursue the applicable abbreviated approval pathway without relying on a Paragraph IV patent challenge.
Does Versed have exclusivity for pediatric sedation?
No broad current exclusivity should be assumed for pediatric use of legacy midazolam. Any protection would depend on a specific product, indication, patent listing, and jurisdiction.
Which midazolam product has the strongest commercial protection?
Newer delivery systems, particularly intranasal or transmucosal products, can have stronger protection than injectable midazolam because their value may depend on formulation, device, dosing, and method-of-use rights.
References
- U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Food and Drug Administration. (n.d.-c). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
- U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
- Roche Holding AG. (2024). Annual report 2023. https://www.roche.com/investors/reports
- U.S. Food and Drug Administration. (n.d.-d). Midazolam prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
